Synthorx, Inc. Securities Litigation

If you purchased a significant amount of shares of Synthorx, Inc. (NASDAQ: THOR), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Synthorx, Inc.
Date Filed:January 3rd, 2020
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:December 9th, 2019
Class End Date:January 3rd, 2020

According to the Complaint, Synthorx is a clinical-stage biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders.

This action stems from a proposed transaction announced on December 9, 2019, pursuant to which Synthorx will be acquired by Sanofi.

On December 7, 2019, Synthorx's Board of Directors caused Synthorx to enter into an agreement and plan of merger with Sanofi.

On December 23, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Synthorx, Inc.

 
First Identified Complaint

Michael Kent, et al. v. Synthorx, Inc., et al.

Date Filed:January 3rd, 2020
Class Period Start:December 9th, 2019
Class Period End:January 3rd, 2020
First Identified Complaint Filings
#Document TitleFiling Date